Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial (Q91147767)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 January 2019

Language	Label	Description	Also known as
English	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial	scientific article published on 18 January 2019

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

phase III clinical trial

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

author name string

Andrew X Zhu

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Yoon-Koo Kang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Chia-Jui Yen

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Richard S Finn

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Peter R Galle

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Eric Assenat

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Giovanni Brandi

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Marc Pracht

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Ho Yeong Lim

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Kun-Ming Rau

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Kenta Motomura

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Izumi Ohno

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Philippe Merle

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Bruno Daniele

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Dong Bok Shin

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Christophe Borg

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Jean-Baptiste Hiriart

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Takuji Okusaka

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Manabu Morimoto

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Yanzhi Hsu

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Paolo B Abada

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Masatoshi Kudo

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

REACH-2 study investigators

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

publication date

18 January 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

282-296

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Molecular therapies and precision medicine for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study. (HEP-17-0903).

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis prediction and staging

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dynamically prognosticating patients with hepatocellular carcinoma through survival paths mapping based on time-series data.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Using serum α-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff?

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(18)30937-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(18)30937-9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30665869 AND SRC:MED&resulttype=core&format=json

20 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q91147767&oldid=2240365099"